10-Q · April 30, 2026
Summit Therapeutics reported a significant net loss of $189.4 million for Q1 2026, exacerbated by rising operational and R&D expenses primarily due to ongoing clinical trials for ivonescimab. Operating expenses rose to…
SMMT earnings analysis
10-Q · Filed November 4, 2026 · Our reading of the company's report
The latest report
Summit’s Q3 2026 loss narrowed year over year, with EPS improving to $(0.26) from $(0.31), but the company remains pre-revenue and its operating cash burn increased materially to $423.229 million for the first nine…
Read full summary
Summit’s Q3 2026 loss narrowed year over year, with EPS improving to $(0.26) from $(0.31), but the company remains pre-revenue and its operating cash burn increased materially to $423.229 million for the first nine months. R&D expense rose 29% year over year in the quarter as clinical programs expanded, while the October $2.0 billion AstraZeneca investment substantially improved near-term liquidity. The November 14, 2026 FDA decision remains the key catalyst and risk because the FDA indicated that statistically significant overall-survival benefit may be required for approval.
Reported figures
- Earnings per share
- $-0.26
- Segment
- Single reportable operating segment; Q3 2026 total segment expenses were $214.611 million, including $122.612 million of oncology clinical trial costs, $32.688 million of compensation costs excluding stock-based compensation, $47.686 million of stock-based compensation, and $11.625 million of other expenses.
What stood out
-
Loss and EPS improved year over year
Q3 2026 net loss narrowed to $208.385 million from $231.793 million in Q3 2025, while diluted EPS improved to $(0.26) from $(0.31). EPS also improved from $(0.28) in Q2 2026 based on the quarterly history.
-
R&D spending accelerated
Research and development expense increased $38.0 million, or approximately 29%, year over year to $169.1 million in Q3 2026, primarily due to higher clinical-trial activity, manufacturing and materials spending, and trial start-up costs.
-
Clinical investment continued to scale
Q3 2026 oncology clinical trial-related costs were $122.612 million, up from $75.236 million in Q3 2025, reflecting increased activity across HARMONi-3, HARMONi-7, HARMONi-GI3 and HARMONi-GU1.
-
Updated HARMONi survival data positive
The June 2026 HARMONi OS analysis showed an overall survival hazard ratio of 0.76 with a nominal p-value of 0.0151 in the global intention-to-treat population; the western subgroup also had a hazard ratio of 0.76.
-
AstraZeneca financing materially strengthened liquidity
The company received $2.0 billion of gross proceeds from AstraZeneca on October 5, 2026. Stockholders also approved the charter amendment on November 4, 2026, a condition to converting the preferred stock into up to 108,955,369 common shares.
-
Liquidity resources expanded
The company had $150.811 million of cash and cash equivalents and $478.976 million of short-term investments at September 30, 2026, while the second ATM retained approximately $354.292 million of gross capacity.
What to watch
-
FDA approval remains uncertain
The FDA’s PDUFA goal action date for the ivonescimab BLA is November 14, 2026, but the FDA stated that a statistically significant overall-survival benefit is necessary and that the study’s progression-free-survival results may not be sufficient for approval.
-
Operating cash burn remains substantial
Cash used in operating activities increased to $423.229 million for the nine months ended September 30, 2026 from $220.992 million in the prior-year period. Management expects operating losses to continue for the foreseeable future.
-
Clinical development costs are rising
Research and development expense rose to $459.482 million for the first nine months of 2026 from $390.382 million, and management expects R&D expenses to continue increasing as ivonescimab development progresses.
-
Large contingent license obligations
The Akeso license includes potential regulatory and commercial milestone payments of up to $4.555 billion, in addition to low-double-digit royalties on net sales; the company stated it may need additional capital to fund these obligations.
-
Profitability and financing dependence
The company reported $2.907668 billion of accumulated deficit at September 30, 2026 and stated that it will need to raise additional capital until it generates substantial product revenue and achieves profitability.
-
No formal risk-factor changes; execution risk persists
The company reported that there were no material changes to the risk factors disclosed in its Annual Report. Nevertheless, the HARMONi-3 squamous-cohort primary PFS events are expected in Q4 2026, while the non-squamous cohort PFS analysis is expected in the first half of 2027, extending clinical and regulatory execution risk.
Management's outlook
No quantitative revenue, EPS, or cash-flow guidance was provided. Management expects research and development and general and administrative expenses to continue increasing, and expects operating losses for the foreseeable future. The company stated that cash, cash equivalents and short-term investments provide sufficient funding for operating cash needs for at least the next 12 months following the $2.0 billion AstraZeneca investment.
Earlier filings 1
Smart money in SMMT
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every SMMT trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.